<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7426275\results\search\disease\results.xml">
  <result pre="high throughput discovery and mechanistic study of antiviral agents against" exact="yellow fever" post="virus GaoZhaoaZhangLinaMaJuliaaJuradoAndreabHongSeon-HuibGuoJu-TaoaRiceCharles M.bMacDonaldMargaret R.bChangJinhongaâˆ—[a], [b], âˆ—Corresponding author. pmc-release: 2020-8-8ppub:"/>
  <result pre="- including this research content - immediately available in PubMed" exact="Central" post="and other publicly funded repositories, such as the WHO"/>
  <result pre="remains active. Abstract Despite the availability of a highly effective" exact="yellow fever" post="virus (YFV) vaccine, outbreaks of yellow fever frequently occur"/>
  <result pre="a highly effective yellow fever virus (YFV) vaccine, outbreaks of" exact="yellow fever" post="frequently occur in Africa and South America with significant"/>
  <result pre="non-structural proteins and demonstrated these antibody reagents in conjunction with" exact="viral" post="RNA metabolic labeling, double-stranded RNA staining and membrane floatation"/>
  <result pre="powerful tools for investigating YFV polyprotein processing, replication complex formation," exact="viral" post="RNA synthesis and high throughput discovery of antiviral drugs."/>
  <result pre="discovery of antiviral drugs. Specifically, the proteolytic processing of the" exact="viral" post="polyprotein can be analyzed by Western blot assays. The"/>
  <result pre="of NS5 protein as well as the relationship between intracellular" exact="viral" post="non-structural protein distribution and foci of YFV RNA replication"/>
  <result pre="Highlights â€¢Lack of antivirals compromises the efforts to control the" exact="yellow fever" post="virus outbreak. â€¢Antibodies of various YFV proteins facilitate study"/>
  <result pre="outbreak. â€¢Antibodies of various YFV proteins facilitate study of YFV" exact="infection" post="and pathogenesis. â€¢Development of antibody-based assays provide tools for"/>
  <result pre="assays is useful for MOA study of YFV antivirals. Keywords" exact="Yellow fever" post="virus Antibody Antiviral assay High throughput screening Antiviral 1"/>
  <result pre="for MOA study of YFV antivirals. Keywords Yellow fever virus" exact="Antibody" post="Antiviral assay High throughput screening Antiviral 1 Introduction Yellow"/>
  <result pre="virus Antibody Antiviral assay High throughput screening Antiviral 1 Introduction" exact="Yellow fever" post="is a mosquito-borne disease caused by yellow fever virus"/>
  <result pre="throughput screening Antiviral 1 Introduction Yellow fever is a mosquito-borne" exact="disease" post="caused by yellow fever virus (YFV) infection and frequently"/>
  <result pre="1 Introduction Yellow fever is a mosquito-borne disease caused by" exact="yellow fever" post="virus (YFV) infection and frequently associated with a severe"/>
  <result pre="is a mosquito-borne disease caused by yellow fever virus (YFV)" exact="infection" post="and frequently associated with a severe form of hemorrhagic"/>
  <result pre="rate of up to 60% (Monath and Vasconcelos, 2015). YFV" exact="infection" post="can be prevented by the attenuated 17D vaccine and"/>
  <result pre="and vaccination campaigns has significantly reduced the incidence of YFV" exact="infection" post="in the human population. However, the virus remains in"/>
  <result pre="also globally. Concern has been raised regarding the possibility of" exact="yellow fever" post="taking hold in previously unaffected and unvaccinated parts of"/>
  <result pre="conspire to promote YFV dissemination. In 2016, there were urban" exact="yellow fever" post="outbreaks in Angola and Democratic Republic of Congo, which"/>
  <result pre="was another urban outbreak in Brazil. While the number of" exact="yellow fever" post="cases are significantly underreported due to the undeveloped nature"/>
  <result pre="areas, it is estimated that up to 1.7 million YFV" exact="infections" post="occur in Africa each year resulting in 29,000â€&quot;60,000 deaths"/>
  <result pre="2018). This outnumbers the estimated death toll of global dengue" exact="virus infection" post="(http://www.who.int/mediacentre/factsheets/fs100/en/). The World Health Organization and its partners responded"/>
  <result pre="This outnumbers the estimated death toll of global dengue virus" exact="infection" post="(http://www.who.int/mediacentre/factsheets/fs100/en/). The World Health Organization and its partners responded"/>
  <result pre="Organization and its partners responded to these recent outbreaks of" exact="yellow fever" post="and emphasized the importance of additional research and the"/>
  <result pre="and vaccination policy remains the best strategy to control global" exact="yellow fever" post="endemics and epidemics, it is anticipated that other yellow"/>
  <result pre="yellow fever endemics and epidemics, it is anticipated that other" exact="yellow fever" post="outbreaks will occur in the near future. Therefore, it"/>
  <result pre="to develop safe and highly efficacious antiviral strategies against YFV" exact="infection" post="that can be used not only for treating infected"/>
  <result pre="no antiviral drug available for the treatment and/or prevention of" exact="yellow fever" post="(Beasley et al., 2015; Douam and Ploss, 2018; Julander,"/>
  <result pre="antiviral agents against emerging flaviviruses such as dengue virus (DENV)," exact="Japanese encephalitis" post="virus (JEV), and Zika virus (ZIKV) (Lim et al.,"/>
  <result pre="agents against emerging flaviviruses such as dengue virus (DENV), Japanese" exact="encephalitis" post="virus (JEV), and Zika virus (ZIKV) (Lim et al.,"/>
  <result pre="be sufficient to prevent and ultimately eliminate the disease. Improving" exact="yellow fever" post="management through the development of effective therapeutics will require"/>
  <result pre="biology and pathogenesis of YFV, knowledge of which remains surprisingly" exact="limited" post="given YFV's medical significance. Like other flaviviruses, YFV has"/>
  <result pre="The genome encodes a polyprotein that is co-translationally processed by" exact="viral" post="and host cellular proteases into three structural proteins (i.e.,"/>
  <result pre="and pathogenesis. Currently, the commercially available YFV antibodies are only" exact="limited" post="to the envelope and NS1 proteins. A couple of"/>
  <result pre="several antibody-based assays and demonstrated their utility, in conjunction with" exact="viral" post="RNA metabolic labeling, double stranded RNA staining and membrane"/>
  <result pre="and membrane floatation assays, in molecular and cellular analyses of" exact="viral" post="proteins and RNA synthesis in YFV infection, antiviral drug"/>
  <result pre="promotor driven luciferase, as previously described (Guo et al., 2014)." exact="Yellow fever" post="virus 17D strain was generated from a cDNA clone,"/>
  <result pre="al., 2003; Guo et al., 2016; Rice et al., 1985)." exact="Yellow fever" post="virus Asibi strain was generated from a slightly modified"/>
  <result pre="antibody was purchased from English &amp;amp; Scientific Consulting, Szirak, Hungary." exact="Mouse" post="monoclonal antibodies against Î²-actin and Hsp70 were purchased from"/>
  <result pre="against Î²-actin and Hsp70 were purchased from Cell Signaling Technology." exact="Mouse" post="monoclonal antibodies against calnexin was obtained from GeneTex. Alexa"/>
  <result pre="Summary of YFV antibodies from GeneTex, Inc. Table 1 YFV" exact="Antibody" post="Catalog No. Immunogen Capsid antibody GTX134022 Full-length capsid recombinant"/>
  <result pre="at 1:1000 dilution. The bound antibodies were visualized with IRDye" exact="secondary" post="antibodies (IRDye 800CW Goat anti-Rabbit IgG and IRDye 680RD"/>
  <result pre="anti-Mouse IgG) and by imaging with the LI-COR Odyssey system." exact="Mouse" post="monoclonal antibody against Î²-actin was used as a loading"/>
  <result pre="24-well plates and infected with YFV at 1 multiplicity of" exact="infection" post="(MOI) for 24Â h. The cells were either fixed"/>
  <result pre="for 1Â h, the cells were incubated with the corresponding" exact="primary" post="antibodies at 4Â Â°C overnight. Subsequently, the cells were"/>
  <result pre="times with 0.1% Tween-20 in PBS (PBST) and stained with" exact="secondary" post="antibodies. Cell nuclei were counterstained with 4â€²,6-diamidine-2â€²-phenylindole dihydrochloride (DAPI)"/>
  <result pre="with ProLong Gold Antifade Mountant (ThermoFisher Scientific). Images were sequentially" exact="acquired" post="on an FV1000 confocal microscope with a PlanApoN 60Â"/>
  <result pre="with a PlanApoN 60Â Ã—Â /1.42 numerical aperture objective (Olympus)." exact="Primary" post="antibodies against YFV capsid (GTX134022), Envelope (GTX134024), prM (GTX133957),"/>
  <result pre="(GEX133958, GTX133959) or NS5 (GTX134141) were used at 1:200 dilution." exact="Antibody" post="against NS4B (GTX134030) was used at 1:500 dilution. J2"/>
  <result pre="Goat anti-Rabbit 594 IgG (HÂ +Â L) were used as" exact="secondary" post="antibodies at 1:250 dilution. 2.5 Visualization of nascent YFV"/>
  <result pre="was performed in accordance to the manufacturer's instructions. Images were" exact="acquired" post="on an FV1000 confocal microscope (Olympus) with a PlanApoN"/>
  <result pre="the top of the gradient. In some experiment, after the" exact="primary" post="membrane floatation, the ER-membrane-enriched fraction was collected and divided"/>
  <result pre="followed by centrifugation at 12,000Ã—g for 10Â min. Detection of" exact="viral" post="and host proteins in each fraction in a Western"/>
  <result pre="(LI-COR) or IRDyeÂ® 800CW Goat anti-Rabbit IgG were used as" exact="secondary" post="antibodies at 1:2000 dilution. Cell viability was determined with"/>
  <result pre="YFV at a MOI of 1. At 48Â h post-infection," exact="total" post="cellular RNA was extracted using TRIzol Reagent (Thermo Fisher"/>
  <result pre="post-infection, total cellular RNA was extracted using TRIzol Reagent (Thermo" exact="Fisher" post="Scientific). YFV RNA was detected in a quantitative reverse"/>
  <result pre="Goat anti-Rabbit 594 IgG (HÂ +Â L) was used as" exact="secondary" post="antibody at 1:300. Cell nuclei were stained with DAPI"/>
  <result pre="(ThermoFisher) to calculate average percent of NS4B positive cells or" exact="total" post="immunofluorescence intensity. 2.11 Statistical analysis Zâ€² factor (Zâ€²) was"/>
  <result pre="raised by immunization of rabbits with synthetic peptides or recombinant" exact="viral" post="proteins, had become commercially available from GeneTex, Inc.. The"/>
  <result pre="M proteins in the lysates of YFV-infected cells. While the" exact="upper" post="band has a size corresponding to prM, the lower"/>
  <result pre="the upper band has a size corresponding to prM, the" exact="lower" post="weaker band is consistent with M (Zheng et al.,"/>
  <result pre="the bands detected after incubation with the indicated rabbit polyclonal" exact="primary" post="antibodies against YFV proteins and the IRDye 800CW Goat"/>
  <result pre="against YFV proteins and the IRDye 800CW Goat anti-Rabbit IgG" exact="secondary" post="antibody. Î²-actin, shown in red, is an internal control,"/>
  <result pre="an internal control, and was detected by a mouse monoclonal" exact="primary" post="antibody and the IRDye 680RD Goat anti-Mouse IgG secondary"/>
  <result pre="monoclonal primary antibody and the IRDye 680RD Goat anti-Mouse IgG" exact="secondary" post="antibody. A pre-stained protein molecular weight marker, shown on"/>
  <result pre="the ability of these YFV antibodies to detect the corresponding" exact="viral" post="proteins in YFV-infected cells using an indirect immunofluorescence assay."/>
  <result pre="(B). After blocking, the cells were incubated with the indicated" exact="primary" post="rabbit polyclonal antibody (NS1 was detected with GTX134025, and"/>
  <result pre="and Alexa Fluor Goat anti-Rabbit 594 IgG (HÂ +Â L)" exact="secondary" post="antibody. Cell nuclei were counterstained with DAPI. Mock-infected cells"/>
  <result pre="non-structural proteins and their spatial relationship with dsRNA and nascent" exact="viral" post="RNA in the cytoplasm The flavivirus genome replication takes"/>
  <result pre="vesicles formed by ER membrane rearrangement induced by the membrane-associated" exact="viral" post="nonstructural proteins such as NS4A and NS4B. This process"/>
  <result pre="proteins co-localized with double-stranded RNAs (dsRNAs) (Fig. 3), the putative" exact="viral" post="RNA replication intermediates that localize in the replication-hosting vesicles"/>
  <result pre="electron tomography studies of DENV-infected cells revealed that newly synthesized" exact="viral" post="RNAs bud through vesicle pores and release of virion"/>
  <result pre="DENV-infected cells revealed that newly synthesized viral RNAs bud through" exact="vesicle" post="pores and release of virion particles into the ER"/>
  <result pre="with previous reports in DENV-infected cells (Miller et al., 2006)," exact="localized" post="predominantly in the nuclei of YFV-infected cells. Consistent with"/>
  <result pre="polymerase function, electron tomography has identified DENV NS5 protein also" exact="localized" post="in the cytoplasmic vesicles, the presumed sites of flavivirus"/>
  <result pre="and Alexa Fluor Goat anti-Rabbit 594 IgG (HÂ +Â L)" exact="secondary" post="antibody. dsRNA was detected by mouse monoclonal primary antibody"/>
  <result pre="+Â L) secondary antibody. dsRNA was detected by mouse monoclonal" exact="primary" post="antibody J2 and Alexa Fluor Goat anti-Mouse 488 IgG"/>
  <result pre="Î¼M. White arrows indicate uninfected cells. In order to detect" exact="viral" post="RNA synthesis in situ in infected cells, the nascent"/>
  <result pre="viral RNA synthesis in situ in infected cells, the nascent" exact="viral" post="RNA can also be metabolically labeled by incorporation of"/>
  <result pre="and Salic, 2008). This assay allows for the visualization of" exact="viral" post="RNA replication foci and determine their spatial relationship with"/>
  <result pre="viral RNA replication foci and determine their spatial relationship with" exact="viral" post="and cellular proteins. The experimental procedure is dipitcted in"/>
  <result pre="D treatment that specifically inhibits DNA-dependent RNA transcription, the RNA-dependent" exact="viral" post="RNA synthesis can be specifically detected only in the"/>
  <result pre="in the cytoplasm of YFV infected cells. As anticipated, the" exact="cytosolic" post="EU click signals, or the newly synthesized viral RNA,"/>
  <result pre="anticipated, the cytosolic EU click signals, or the newly synthesized" exact="viral" post="RNA, colocalized with NS4B protein (Fig. 4C). Although the"/>
  <result pre="the click chemistry technologies have been used for studying RNA-dependent" exact="viral" post="RNA synthesis in the cells infected with Ebolavirus (Hoenen"/>
  <result pre="in the cells infected with Ebolavirus (Hoenen et al., 2012)," exact="chikungunya" post="virus (Reid et al., 2015) or coronavirus (Hagemeijer et"/>
  <result pre="in infected cells. In conjunction with the immunofluorescent detection of" exact="viral" post="nonstructural proteins, the click chemical visualization of intracellular viral"/>
  <result pre="of viral nonstructural proteins, the click chemical visualization of intracellular" exact="viral" post="RNA synthesis may not only reveal viral and host"/>
  <result pre="visualization of intracellular viral RNA synthesis may not only reveal" exact="viral" post="and host cellular proteins at viral RNA replication foci,"/>
  <result pre="may not only reveal viral and host cellular proteins at" exact="viral" post="RNA replication foci, but also provide a powerful tool"/>
  <result pre="also provide a powerful tool for in situ analyses of" exact="viral" post="RNA replication and its inhibition by antiviral drugs. Fig."/>
  <result pre="100Â Î¼M. White arrows indicate uninfected cells. 3.4 Investigation of" exact="viral" post="protein association with cellular membranes by membrane flotation assay"/>
  <result pre="ER-membrane-derived vesicles and assemble progeny virions at ER or ER-Golgi" exact="intermediate" post="compartment (ERGIC) membranes. It is, therefore, conceivable that investigating"/>
  <result pre="is, therefore, conceivable that investigating the distribution and interaction of" exact="viral" post="proteins and host cellular components at the distinct intracellular"/>
  <result pre="its inhibition by antiviral agents. To analyze the association of" exact="viral" post="and cellular proteins with intracellular membranes, we utilized a"/>
  <result pre="loaded at the bottom of the gradient, overlaid with the" exact="lower" post="densities of sucrose solutions. The cellular membranes floated up"/>
  <result pre="by Western blot assay with antibodies against organelle markers or" exact="viral" post="and cellular proteins of interest. As shown in Fig."/>
  <result pre="of interest. As shown in Fig. 5 A, as anticipated," exact="viral" post="NS2B, NS4B and envelope proteins were enriched with the"/>
  <result pre="only partially disrupted the membrane and a portion of the" exact="viral" post="proteins were still associated with the detergent-resistant membrane structure,"/>
  <result pre="membrane structure, presumably lipid rafts, while the vast majority of" exact="viral" post="proteins were solubilized under this condition (Fig. 5C). This"/>
  <result pre="detergent resistant membranes (Yi et al., 2012). The lipid rafts-associated" exact="viral" post="proteins have been shown to play distinct role in"/>
  <result pre="viral proteins have been shown to play distinct role in" exact="viral" post="genome replication and virion particle morphogenesis at the ER."/>
  <result pre="been demonstrated in HCV infected cells, further analysis of YFV" exact="viral" post="and host protein-protein interaction in each of these fractions"/>
  <result pre="assays The cytopathic effect (CPE)-based cell viability assay, quantification of" exact="viral" post="RNA by real time RT-PCR assay, and the plaque-based"/>
  <result pre="an interferon Î² promotor-driven-luciferase reporter assay for indirect quantification of" exact="viral" post="RNA replication and discovery of antiviral drugs, including YFV"/>
  <result pre="(designated as BDAA) (Guo et al., 2016) dose-dependently inhibited YFV" exact="infection" post="as judged by a significantly reduced fluorescence intensity revealed"/>
  <result pre="per sample in 384-well format. Thus, we can determine the" exact="total" post="number of cells and the number of NS4B-positive cells"/>
  <result pre="the 384-well plate) using percentage cells with NS4B signal or" exact="total" post="immunofluorescence intensity. The two types of analyses reveal a"/>
  <result pre="antibody against NS3, NS4B or pan-flavivirus monoclonal antibody 4G2 as" exact="primary" post="antibody, with IRDyeÂ® 800CW goat anti-Rabbit or anti-Mouse as"/>
  <result pre="primary antibody, with IRDyeÂ® 800CW goat anti-Rabbit or anti-Mouse as" exact="secondary" post="antibodies. Cells were stained with DRAQ5 and Sapphire700. YFV"/>
  <result pre="Quantitation of percentage of cells with positive NS4B signal and" exact="total" post="fluorescence intensity were calculated based on multiple images taken"/>
  <result pre="the reliability of the qRT-PCR assay can be affected by" exact="viral" post="strain diversity. The yield reduction assay is labor-intensive. These"/>
  <result pre="antiviral agents for all the druggable targets, including not only" exact="viral" post="components but also cellular factors required for viral replication."/>
  <result pre="not only viral components but also cellular factors required for" exact="viral" post="replication. Table 2 Antiviral activity of BDAA determined by"/>
  <result pre="YFV RNA 0.18Â Â±Â 0.1 0.28Â Â±Â 0.05 Yield reductionc" exact="Viral" post="plaque 0.32Â Â±Â 0.15 1.35Â Â±Â 0.13 In-cell westernd"/>
  <result pre="supports the notion of combination of antivirals targeting two distinct" exact="viral" post="proteins to maximize therapeutic benefit. Fig. 7 Development of"/>
  <result pre="YFV. References References AdungoF.YuF.KamauD.InoueS.HayasakaD.Posadas-HerreraG.SangR.MwauM.MoritaK.Development and characterization of monoclonal antibodies to" exact="yellow fever" post="virus and application in antigen detection and IgM capture"/>
  <result pre="therapyAntivir. Res.1152015487025545072 BlightK.J.McKeatingJ.A.RiceC.M.Highly permissive cell lines for subgenomic and genomic" exact="hepatitis C" post="virus RNA replicationJ. Virol.762002130011301412438626 BoyerA.DreneauJ.DumansA.Burlaud-GaillardJ.Bull-MaurerA.RoingeardP.MeunierJ.C.Endoplasmic reticulum detergent-resistant membranes accommodate"/>
  <result pre="C virus RNA replicationJ. Virol.762002130011301412438626 BoyerA.DreneauJ.DumansA.Burlaud-GaillardJ.Bull-MaurerA.RoingeardP.MeunierJ.C.Endoplasmic reticulum detergent-resistant membranes accommodate" exact="hepatitis C" post="virus proteins for viral assemblyCells82019 BredenbeekP.J.KooiE.A.LindenbachB.HuijkmanN.RiceC.M.SpaanW.J.A stable full-length yellow"/>
  <result pre="BoyerA.DreneauJ.DumansA.Burlaud-GaillardJ.Bull-MaurerA.RoingeardP.MeunierJ.C.Endoplasmic reticulum detergent-resistant membranes accommodate hepatitis C virus proteins for" exact="viral" post="assemblyCells82019 BredenbeekP.J.KooiE.A.LindenbachB.HuijkmanN.RiceC.M.SpaanW.J.A stable full-length yellow fever virus cDNA clone"/>
  <result pre="membranes accommodate hepatitis C virus proteins for viral assemblyCells82019 BredenbeekP.J.KooiE.A.LindenbachB.HuijkmanN.RiceC.M.SpaanW.J.A" exact="stable" post="full-length yellow fever virus cDNA clone and the role"/>
  <result pre="hepatitis C virus proteins for viral assemblyCells82019 BredenbeekP.J.KooiE.A.LindenbachB.HuijkmanN.RiceC.M.SpaanW.J.A stable full-length" exact="yellow fever" post="virus cDNA clone and the role of conserved RNA"/>
  <result pre="polyfunctional immune responsesJ. Exp. Med.20520083119313119047440 GuoF.WuS.JulanderJ.MaJ.ZhangX.KulpJ.CuconatiA.BlockT.M.DuY.GuoJ.T.ChangJ.A novel benzodiazepine compound inhibits" exact="yellow fever" post="virus infection by specifically targeting NS4B proteinJ. Virol.90201615 GuoF.ZhaoX.GillT.ZhouY.CampagnaM.WangL.LiuF.ZhangP.DiPaoloL.DuY.XuX.JiangD.WeiL.CuconatiA.BlockT.M.GuoJ.T.ChangJ.An"/>
  <result pre="responsesJ. Exp. Med.20520083119313119047440 GuoF.WuS.JulanderJ.MaJ.ZhangX.KulpJ.CuconatiA.BlockT.M.DuY.GuoJ.T.ChangJ.A novel benzodiazepine compound inhibits yellow fever" exact="virus infection" post="by specifically targeting NS4B proteinJ. Virol.90201615 GuoF.ZhaoX.GillT.ZhouY.CampagnaM.WangL.LiuF.ZhangP.DiPaoloL.DuY.XuX.JiangD.WeiL.CuconatiA.BlockT.M.GuoJ.T.ChangJ.An interferon-beta promoter"/>
  <result pre="Exp. Med.20520083119313119047440 GuoF.WuS.JulanderJ.MaJ.ZhangX.KulpJ.CuconatiA.BlockT.M.DuY.GuoJ.T.ChangJ.A novel benzodiazepine compound inhibits yellow fever virus" exact="infection" post="by specifically targeting NS4B proteinJ. Virol.90201615 GuoF.ZhaoX.GillT.ZhouY.CampagnaM.WangL.LiuF.ZhangP.DiPaoloL.DuY.XuX.JiangD.WeiL.CuconatiA.BlockT.M.GuoJ.T.ChangJ.An interferon-beta promoter"/>
  <result pre="yellow feverAntivir. Res.97201316917923237991 KlittingR.FischerC.DrexlerJ.F.GouldE.A.RoizD.PaupyC.de LamballerieX.What does the future hold for" exact="yellow fever" post="virus? (II)Genes92018 KlittingR.GouldE.A.PaupyC.de LamballerieX.What does the future hold for"/>
  <result pre="fever virus? (II)Genes92018 KlittingR.GouldE.A.PaupyC.de LamballerieX.What does the future hold for" exact="yellow fever" post="virus? (I)Genes92018 KumarA.BuhlerS.SeliskoB.DavidsonA.MulderK.CanardB.MillerS.BartenschlagerR.Nuclear localization of dengue virus nonstructural protein"/>
  <result pre="virus nonstructural protein 5 does not strictly correlate with efficient" exact="viral" post="RNA replication and inhibition of type I interferon signalingJ."/>
  <result pre="strictly correlate with efficient viral RNA replication and inhibition of" exact="type I" post="interferon signalingJ. Virol.8720134545455723408610 LescarJ.SohS.LeeL.T.VasudevanS.G.KangC.LimS.P.The dengue virus replication complex: from"/>
  <result pre="mannerJ. Biol. Chem.28220078873888217276984 MillerS.SparacioS.BartenschlagerR.Subcellular localization and membrane topology of the" exact="Dengue" post="virus type 2 Non-structural protein 4BJ. Biol. Chem.28120068854886316436383 MonathT.P.VasconcelosP.F.Yellow"/>
  <result pre="Chem.28220078873888217276984 MillerS.SparacioS.BartenschlagerR.Subcellular localization and membrane topology of the Dengue virus" exact="type 2" post="Non-structural protein 4BJ. Biol. Chem.28120068854886316436383 MonathT.P.VasconcelosP.F.Yellow feverJ. Clin. Virol.64201516017325453327"/>
  <result pre="Biol. Chem.28120068854886316436383 MonathT.P.VasconcelosP.F.Yellow feverJ. Clin. Virol.64201516017325453327 PatkarC.G.LarsenM.OwstonM.SmithJ.L.KuhnR.J.Identification of inhibitors of" exact="yellow fever" post="virus replication using a replicon-based high-throughput assayAntimicrob. Agents Chemother.5320094103411419651907"/>
  <result pre="multidrug therapiesAntivir. Ther.1199692011322261 QuerecT.D.AkondyR.S.LeeE.K.CaoW.NakayaH.I.TeuwenD.PiraniA.GernertK.DengJ.MarzolfB.KennedyK.WuH.BennounaS.OluochH.MillerJ.VencioR.Z.MulliganM.AderemA.AhmedR.PulendranB.Systems biology approach predicts immunogenicity of the" exact="yellow fever" post="vaccine in humansNat. Immunol.10200911612519029902 ReidS.P.TritschS.R.KotaK.ChiangC.Y.DongL.KennyT.BrueggemannE.E.WardM.D.CazaresL.H.BavariS.Sphingosine kinase 2 is a"/>
  <result pre="fever vaccine in humansNat. Immunol.10200911612519029902 ReidS.P.TritschS.R.KotaK.ChiangC.Y.DongL.KennyT.BrueggemannE.E.WardM.D.CazaresL.H.BavariS.Sphingosine kinase 2 is a" exact="chikungunya" post="virus host factor co-localized with the viral replication complexEmerg."/>
  <result pre="2 is a chikungunya virus host factor co-localized with the" exact="viral" post="replication complexEmerg. Microb. Infect.42015e61 Ricciardi-JorgeT.BordignonJ.KoishiA.ZanlucaC.MosimannA.L.Duarte Dos SantosC.N.Development of a"/>
  <result pre="a quantitative NS1-capture enzyme-linked immunosorbent assay for early detection of" exact="yellow fever" post="virus infectionSci. Rep.720171622929176643 RiceC.M.LenchesE.M.EddyS.R.ShinS.J.SheetsR.L.StraussJ.H.Nucleotide sequence of yellow fever virus:"/>
  <result pre="detection of yellow fever virus infectionSci. Rep.720171622929176643 RiceC.M.LenchesE.M.EddyS.R.ShinS.J.SheetsR.L.StraussJ.H.Nucleotide sequence of" exact="yellow fever" post="virus: implications for flavivirus gene expression and evolutionScience22919857267334023707 StadlerK.AllisonS.L.SchalichJ.HeinzF.X.Proteolytic"/>
  <result pre="implications for flavivirus gene expression and evolutionScience22919857267334023707 StadlerK.AllisonS.L.SchalichJ.HeinzF.X.Proteolytic activation of" exact="tick-borne encephalitis" post="virus by furinJ. Virol.711997847584819343204 StockN.K.EscadafalC.AchaziK.CisseM.NiedrigM.Development and characterization of polyclonal"/>
  <result pre="for flavivirus gene expression and evolutionScience22919857267334023707 StadlerK.AllisonS.L.SchalichJ.HeinzF.X.Proteolytic activation of tick-borne" exact="encephalitis" post="virus by furinJ. Virol.711997847584819343204 StockN.K.EscadafalC.AchaziK.CisseM.NiedrigM.Development and characterization of polyclonal"/>
  <result pre="and characterization of polyclonal peptide antibodies for the detection of" exact="Yellow fever" post="virus proteinsJ Virol Methods222201511011626086983 WelschS.MillerS.Romero-BreyI.MerzA.BleckC.K.WaltherP.FullerS.D.AntonyC.Krijnse-LockerJ.BartenschlagerR.Composition and three-dimensional architecture of"/>
  <result pre="envelope proteinsNat. Commun.52014387724846574 ZmurkoJ.NeytsJ.DallmeierK.Flaviviral NS4b, chameleon and jack-in-the-box roles in" exact="viral" post="replication and pathogenesis, and a molecular target for antiviral"/>
  <result pre="(AI134732 and AI124690) and the 10.13039/100007032Commonwealth of Pennsylvania through the" exact="Hepatitis" post="B Foundation."/>
 </snippets>
</snippetsTree>
